RadNet stock has delivered a strong 136.9% return over the past 5 years, yet today investors face mixed valuation signals as an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach screens the shares as undervalued while market multiples point to a richer price.

• Over 5 years RadNet has returned 136.9%, which puts extra focus on whether the current share price still leaves room for an attractive risk adjusted payoff.
• The recent FDA clearance for DeepHealth Breast Ultrasound can support expectations for longer term cash flow growth, while execution risks around rolling the technology out across RadNet's network may limit how much value the market is willing to ascribe upfront.
• RadNet scores 4 out of 6 on the broader valuation checks, which points to a mixed picture rather than a clear bargain or an obviously expensive stock.

The issue now is whether the DCF based intrinsic value case or the richer market multiple view ends up being the more reliable guide for where RadNet belongs on the valuation spectrum.

Is RadNet Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model values RadNet by projecting future cash the business can return to shareholders and discounting it back to today. For RadNet, the model uses latest twelve month free cash flow of about $112.5 million and assumes that cash flows keep growing rather than flattening or shrinking. On that basis, the DCF model arrives at an estimated intrinsic value of about $99 per share.

Compared with the current share price, this implies RadNet screens as roughly 27.2% undervalued. The recent FDA clearance for DeepHealth Breast Ultrasound adds a clear pipeline of potential exams that can support those cash flow expectations, although the market may still be cautious about how smoothly the rollout will go across the network. Overall, the cash flow based valuation points to a gap between what RadNet is currently priced at and what its projected cash generation supports.

On this Discounted Cash Flow view, RadNet stock currently appears undervalued relative to its estimated intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests RadNet is undervalued by 27.2%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Does RadNet Look Pricey on Sales?

P/S is a useful cross check for RadNet because the business model is built around a large and recurring revenue base, while reported earnings and free cash flow can be more cyclical.

RadNet currently trades on a P/S of about 2.7x. This sits above the Healthcare industry average of roughly 1.5x and is also lower than the peer group average of around 3.9x. The valuation model suggests a fair P/S ratio of about 1.1x given RadNet's profile, which is meaningfully below where the stock trades today.

This gap implies investors are paying a premium P/S multiple for RadNet relative to what the fair ratio model indicates, even when compared with both the wider Healthcare sector and closer peers.

On the P/S multiple, RadNet stock currently screens as overvalued.

The RadNet Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for RadNet pick up where this valuation puzzle leaves off. They spell out which assumptions about RadNet's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Rather than focusing on a single multiple or DCF output, each one lays out its own fair value assumptions so you can check them against actual results over time.

You can be one of the first voices in the Simply Wall St community to set out a clear, number driven narrative on RadNet that others can follow over time. Share your view on whether DeepHealth Breast Ultrasound and RadNet's broader execution on that rollout ultimately support today's valuation or call for a different view.

Do you think there's more to the story for RadNet? Head over to our Community to see what others are saying!

The Bottom Line

RadNet sits between two valuation stories. The Discounted Cash Flow (DCF) intrinsic value estimate points to undervaluation, while the P/S multiple suggests the stock is priced on the rich side compared with sector and peer benchmarks. That gap reflects a market that is willing to pay up for revenue and growth expectations, but is more cautious about how those expectations translate into future cash generation and capital needs. The key question from here is whether RadNet can execute on initiatives like DeepHealth Breast Ultrasound at a pace and scale that turn today’s premium revenue multiple into sustained cash flow that justifies the current price.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.